Clinical Microbiology Market Insights - Opportunities and Challenges
2022-05-06 11:04:28 UTC | Healthcare & Pharmaceuticals
According to the new market research report
Clinical Microbiology Market is estimated to be USD 3.9 billion in 2020 and projected to reach USD 5.3 billion by 2025, at a CAGR of 6.5%.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=219135367
Factors
such as the Technological advancements, rising incidence of infectious
diseases and growing outbreak of epidemics (such as COVID-19), and
increased funding and public-private investments are some of the key
factors driving the growth of the microbiological testing/clinical
microbiology market. However, unfavorable reimbursement scenarios in
some countries are hampering the development of the Microbiology Testing
Market.
Based on application, the nuclear medicine market is
segmented into SPECT, PET, and therapeutic applications. The SPECT
applications is further segmented into cardiology, bone scans, thyroid
applications, pulmonary scans, and other SPECT applications. The thyroid
applications segment is projected to register the highest growth rate
in the forecast period. The high growth of this segment can be
attributed to the increasing incidence and prevalence of thyroid
disorders.
On the basis of type, the nuclear medicine market is
segmented into diagnostic and therapeutic. The diagnostic segment
accounted for a larger share of the market 2020. The large share of this
segment can be attributed to the non-invasiveness, increasing
prevalence of cardiovascular diseases and early diagnosis.
Opportunity: Improving healthcare infrastructure across emerging countries
Emerging
markets are expected to offer significant growth opportunities to
clinical microbiology product manufacturers and distributors during the
forecast period. This can be attributed to the growing prevalence of
infectious diseases such as HIV, tuberculosis, influenza, and malaria as
well as increasing R&D initiatives to develop innovative genomic
techniques for efficient disease diagnosis in developing nations.
The
growth in these markets is further supported by improvements in
healthcare infrastructure, growing healthcare expenditure, and
increasing availability and affordability of low-cost clinical
microbiology products. In line with the ongoing trend, several
government initiatives have been undertaken across emerging markets
(particularly in China and India) to strengthen and expand the
healthcare infrastructure.
Challenge: Operational barriers related to the use of diagnostic tests
Diagnostic
microbiology tests involve various types of patient samples, such as
semen, saliva, tissue, blood, and urine. These diagnostic tests have
limited utilization of automated instruments to directly diagnose common
pathogens such as Plasmodium, Staphylococcus, and E. coli. Clinical
laboratories must have proper logistic support for timely sample
collection, efficient transportation, and safe and standardized sample
processing to provide correct and accurate diagnostic results to
patients. However, meeting optimal criteria for sample handling and
transportation is a key challenge faced by a majority of clinical
laboratories. For instance, in the case of preanalytical sample
processing, the sample should be procured at room temperature and
transported at fixed temperatures only. Additionally, clinical
laboratories must verify separate preanalytical and analytical
procedures for individual matrix type so as to get optimal and correct
results.
In 2020, North America accounted for the largest share
of the nuclear medicine market. A large share of North America can be
attributed to the large share can be attributed to the development of
novel technologies for radioisotope production, government funding, and
company initiatives in the region.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=219135367
The
major players operating in the Microbiology Testing Market include
bioMérieux SA (France), Danaher Corporation (US), Becton, Dickinson and
Company (US), Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US),
F. Hoffmann-La Roche AG (Switzerland), Bruker Corporation (US),
Hologic, Inc. (US), QIAGEN N.V. (The Netherlands), Thermo Fisher
Scientific Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA
(Germany), Shimadzu Corporation (Japan), 3M Company (US), and Neogen
Corporation (US), among others.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
Email: sales@marketsandmarkets.com
